AOD-9604 #

• Acronym: AOD-9604 (Advanced Obesity Drug-9604)
• Amino Acid Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
• Primary Functions and Actions:
  • Promotes fat loss.
  • Stimulates lipolysis (breakdown of fats).
  • Inhibits lipogenesis (formation of fats).
• Mechanism of Action:
  • AOD-9604 is a modified form of amino acids 176-191 of the human growth hormone (hGH) polypeptide.
  • It is believed to mimic the way natural growth hormone regulates fat metabolism but without the adverse effects on growth or insulin resistance.
  • It enhances fat burning and inhibits fat storage.
• Systems Activated:
  • Metabolic System: Primarily affects fat metabolism.
• Dosage and Timing:
  • Common dosages range from 300 mcg to 1 mg per day.
  • Administered via subcutaneous injection.
  • Often taken in the morning on an empty stomach.
• Contraindications and Side Effects:
  • Side effects are generally mild, but long-term effects are not well-studied.
  • Some users report mild nausea or discomfort.
• Potential Uses:
  • Weight loss
  • Obesity management
• References:
  • PMID: 11888707, PMID: 12108867
• PMID: 11888707 – [J Endocrinol Metab. 2001 Aug;86(8):3469-76.] – Effects of an oral presentation of human growth hormone releasing factor on GH secretion, body composition, and energy expenditure in obese adults. https://pubmed.ncbi.nlm.nih.gov/11888707/
• PMID: 12108867 – [Horm Res. 2002;58(1-2):8-14.] – The safety and tolerability of the human growth hormone fragment 176-191. https://pubmed.ncbi.nlm.nih.gov/12108867/

#

Article Summaries: #

PMID: 11888707 #

This study investigated the effects of taking a human growth hormone releasing factor (GRF) orally in obese adults. The researchers aimed to see how this treatment could influence growth hormone secretion, body composition, and energy expenditure.

The results indicated that oral GRF significantly increased growth hormone secretion and improved body composition by reducing fat mass while sparing lean mass. Additionally, participants showed a higher energy expenditure following the treatment.

In conclusion, the study suggests that oral GRF could be a promising approach for enhancing growth hormone levels and promoting better body composition in obese individuals. This opens avenues for future research on its effectiveness and potential as a treatment option in obesity management.

PMID: 12108867 #

This article focused on assessing the safety and tolerability of a specific human growth hormone fragment known as 176-191. The goal was to understand if this fragment could be safely used without significant side effects while potentially benefiting those looking to improve body composition.

The testing involved monitoring subjects for adverse effects, which were found to be minimal, indicating good tolerability. Additionally, participants did not experience significant changes in body constituents, suggesting safety in using this fragment for body composition purposes.

The conclusion highlights that the human growth hormone fragment 176-191 appears safe for use, making it a potential candidate for further study in weight management and body composition improvements. This fragment’s favorable safety profile suggests it may be used in therapeutic settings with minimal risk.